TRACON Pharmaceuticals, Inc. (TCON)

OTCMKTS · Delayed Price · Currency is USD
0.150
+0.061 (68.54%)
Sep 18, 2024, 3:24 PM EDT
-97.39%
Market Cap 440.26K
Revenue (ttm) 3.20M
Net Income (ttm) 5.20M
Shares Out 3.41M
EPS (ttm) 2.27
PE Ratio 0.06
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 93,498
Open 0.140
Previous Close 0.089
Day's Range 0.137 - 0.290
52-Week Range 0.002 - 14.750
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Nov 8, 2024

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company’s clinical stage products also in... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 17
Stock Exchange OTCMKTS
Ticker Symbol TCON
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.